Navigation Links
Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
Date:6/10/2008

Ambien CR(R) 12.5 mg significantly improved sleep onset, sleep maintenance

and total sleep time compared to placebo

BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that showed Ambien CR(R) (zolpidem tartrate extended-release) CIV tablets 12.5 mg provided significant improvement in sleep onset, sleep maintenance and total sleep time over 8 weeks in patients with co-morbid insomnia and major depressive disorder (MDD) who were administered a Selective Serotonin Reuptake Inhibitor (SSRI) for depression. Ambien CR also improved sleep-related next-day functioning measures. This data was presented at the SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS).

Thomas Roth, PhD, director of the Sleep Disorders and Research Center at Henry Ford Hospital, states, "The results of this study demonstrate that Ambien CR can be considered a viable treatment option for the insomnia MDD patients experience and help them get the good night's sleep they need to improve their next-day functioning."

Ambien CR Improved Sleep Quality and Sleep Impact on Daily Activities in MDD Patients

Total sleep time was increased in the Ambien CR group throughout the study. At Week eight, patients reporting sleeping an average of 101 minutes more than baseline compared to placebo-treated patients who reported sleeping an average 64 minutes more (P<0.0001). On average, Ambien CR-treated patients reported falling asleep sooner and exhibited improved sleep maintenance based upon fewer nighttime awakenings and decreased wake time after sleep onset compared to placebo-treated patients (P<0.0001). In addition, patients reported improvements in secondary measures related to daytime functioning, including morning energy, morning concentration and sleep impact on daily activities.

Treatment-emergent adverse events occurred in 72.9 percent of the patients treated wi
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
2. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
3. TriMix Gel Achieves Success Among Men Who Have Failed to Achieve Erections With Viagra, Levitra and Cialis Type Tablets
4. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
5. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
6. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
7. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
8. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
9. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
10. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
11. Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2010)... Feb. 8 BD Diagnostics, a ... the launch of BD Microtainer® MAP Microtube for Automated ... to improve the safety, accuracy and turnaround time of ... that can be difficult to access, such as infants, ... Microtainer MAP product is also the first microtube to ...
(Date:2/8/2010)... Hanger Orthopedic Group, Inc. (NYSE: HGR ... of operations for the year ended December 31, 2009 ... Company plans to issue a press release announcing the results ... Wednesday, February 10, 2010 , after the close of ... 9:00 a.m., EST , on Thursday, February 11, ...
(Date:2/8/2010)... Feb. 8 Connectyx Technologies Holdings ... advertising contract with SkyMall Inc. SkyMall produces the ... major airlines seat pockets. SkyMall has an annual ... featuring the MedFlash ® Personal Health Manager ... of contents in the front section of the ...
Breaking Medicine Technology:BD Launches New Device Designed to Improve Safety, Accuracy and Turnaround Time of Blood Collection in Patients with Fragile Veins 2Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call 2Connectyx Announces MedFlash(R) Advertising Contract with SkyMall Inc. 2Connectyx Announces MedFlash(R) Advertising Contract with SkyMall Inc. 3livethesource 28TM 29 the Worlds First and Only Patented Fully Nano Encapsulated Liquid Vitamin Mineral and Herbal Supplement Now Available in Dal 51780 1livethesource 28TM 29 the Worlds First and Only Patented Fully Nano Encapsulated Liquid Vitamin Mineral and Herbal Supplement Now Available in Dal 51780 2livethesource 28TM 29 the Worlds First and Only Patented Fully Nano Encapsulated Liquid Vitamin Mineral and Herbal Supplement Now Available in Dal 51780 3CNCB Post Graduate Studies in Clinical Nutrition 28PGSCN 29 Program is Now Available Online 51778 1CNCB Post Graduate Studies in Clinical Nutrition 28PGSCN 29 Program is Now Available Online 51778 2Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi Year Marketing Agreement with Phase Forward 13043 1Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi Year Marketing Agreement with Phase Forward 13043 2Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi Year Marketing Agreement with Phase Forward 13043 3
... Studies with Monoclonal Antibody,Targeting Interleukin-9 (IL-9); Preclinical ... Developing Potential Asthma,Therapies, GAITHERSBURG, Md., May 24, ... presentation of data,highlighting recent progress within the ... Phase 1 clinical,studies with its monoclonal antibody ...
... HILL, N.C., May 25, 2007 /PRNewswire/ -- ... pharmaceutical product at play,pharmaceutical firms need to ... early. Companies that master,their communication planning and ... marketplace. , According to research and consulting ...
Other Medicine Technology:MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 2Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data 3
(Date:2/9/2010)... Could See Idaho Lose $1.6 Billion from Feds ... Feb. 9 As the Idaho House ... federal health care law, the long-term effects of the move ... the Idaho Health Freedom Act (House Bill 391) a disastrous ... could see Idaho lose nearly $1.6 billion ...
(Date:2/9/2010)... comprehensive study to date of secondhand smoke exposure among ... Addiction . The study, carried out by researchers ... that exposure to household secondhand smoke among children aged ... wanted to find out if there were ways to ... in private households, and whether those levels were changing ...
(Date:2/9/2010)... MINNEAPOLIS/ST.PAUL (February 8, 2010)- Consuming two or more soft ... cancer by nearly two-fold compared with individuals who did ... Cancer Epidemiology, Biomarkers & Prevention , a journal ... Although relatively rare, pancreatic cancer remains one of the ... diagnosed survive five years later. , Mark Pereira, Ph.D., ...
(Date:2/9/2010)... has increased in infants born prematurely in the US, ... Health System (LUHS). These findings were reported at the ... in Chicago. They also were published in the latest ... Gynecology . , Researchers reported that CP is associated ... cord. This inflammation is more common in premature births ...
(Date:2/9/2010)... 2010) AcademyHealth today recognized research that improves patient ... Services Research (HSR) Impact Award. The WHO Surgical ... ensure adherence to basic safety standards of care. ... that clearly translated into policy and, ultimately, made ... W. David Helms, Ph.D. "The WHO Surgical Safety ...
Breaking Medicine News(10 mins):Health News:Idaho House Moves State Closer to Health Care Disaster 2Health News:Idaho House Moves State Closer to Health Care Disaster 3Health News:Idaho House Moves State Closer to Health Care Disaster 4Health News:Exposure to secondhand smoke among children in England has declined since 1996 2Health News:Soft drinks may increase risk of pancreatic cancer 2Health News:Incidence of cerebral palsy on rise in US 2Health News:2010 HSR Impact Award recognizes surgical safety research 2
... March 10 On March 23, the Easter,Bunny will ... goodies.,But, if you,re one of the lucky recipients, make ... your pets. Chocolate is poisonous to,dogs and cats, and ... equally as dangerous., Dr. Gregory S. Hammer, president ...
... Computer,Services, Inc. (NYSE: ACS ) announced today ... contract to provide information technology,outsourcing (ITO) services to ... system., Under the terms of the agreement, ... operations, network,monitoring and management, asset tracking, and help ...
... Therap Services announces,the appointment of Anna Keith ... web-based service bureau offering an integrated suite,of applications ... support team consisting of former executive directors, house,managers, ... happy to have Anna in our team. Anna ...
... have correlated with prostate biopsy results in the detection ... for men with a normal prostate exam, according to ... issue of CANCER, a peer-reviewed journal of the American ... make PSA less useful in prostate cancer screening. , ...
... Fiduciary, Media, Network ... Security and Data Privacy Coverage, ... (NYSE: DR ) has introduced a new,multi-coverage corporate ... comprehensive policy, Darwin has integrated the,following coverage parts, which ...
... Drosophila (fruit flies), have identified several drugs and small molecules ... frequent form of mental retardation and one of the leading ... for developing new treatments for fragile X syndrome. , The ... chair of the Department of Human Genetics at Emory University ...
Other Medicine News:Health News:AVMA: Keep Pets Safe This Easter 2Health News:ACS Awarded $41 Million Contract to Provide IT Outsourcing Services to Parkland Hospital 2Health News:ACS Awarded $41 Million Contract to Provide IT Outsourcing Services to Parkland Hospital 3Health News:Therap Services Welcomes Anna Keith to the US Customer Support Team 2Health News:Biopsy techniques have made PSA test less predictive 2Health News:Darwin Introduces New Managed Care Corporate Liability Insurance 2Health News:Darwin Introduces New Managed Care Corporate Liability Insurance 3Health News:Drosophila drug screen for fragile X syndrome finds promising compounds and potential drug targets 2
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
For the quantitative determination of alanine aminotransferase in serum used in routine examination and monitoring of therapy and relapses....
For the quantitative determination of Alanine Aminotransferase in serum. Optimized IFCC without P-5'-P, Linearity: 500 IU/L at 37 C. Liquid Working Reagent prepared with simple 1:9 dilution....
Medicine Products: